{"publisher":"Bimatoprost Rx","product":"Bimatoprost","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"In a 2012 randomized trial, subjects were randomized over 5 months to once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141). A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) than vehicle (18.4%) demonstrated at least a 1-grade increase in global eyelash assessment score at week 16 (P < .0001). The abstract lists the short-term duration of the trial and that black subjects were not enrolled secondary to technical requirements of digital image analysis as limitations.","href":"https://pubmed.ncbi.nlm.nih.gov/21899919/"},{"label":"Research finding 2","text":"A 2015 randomized controlled trial in patients with idiopathic hypotrichosis reports that treatment effects were maintained for approximately 2 months but markedly diminished 4-6 months following treatment cessation.","href":"https://pubmed.ncbi.nlm.nih.gov/25296533/"},{"label":"Research finding 3","text":"A pooled safety analysis of six randomized trials reports that most adverse events occurred early in treatment, were mild in intensity, localized to treatment site, and reversible with treatment cessation, and that discontinuations due to adverse events were low (3.2% for bimatoprost and 2.4% for vehicle).","href":"https://pubmed.ncbi.nlm.nih.gov/26203317/"},{"label":"Research finding 4","text":"A literature review published in Dermatologic Surgery (2021) states that the literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. It concludes that clinical trials may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy, and that the risk of increased iris pigmentation remains inadequately investigated.","href":"https://pubmed.ncbi.nlm.nih.gov/33625141/"},{"label":"Research finding 5","text":"An observational retrospective chart review of bimatoprost 0.03% found that 27.4% of patients spontaneously recalled experiencing adverse events while on treatment, only 4 adverse events were documented in patient charts, no instances of iris hyperpigmentation occurred, and no serious or severe adverse events were noted. Its author affiliations include Allergan, Inc.","href":"https://pubmed.ncbi.nlm.nih.gov/25229783/"},{"label":"Research finding 6","text":"The FDA says compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed.","href":"https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding"}],"sources":[{"title":"Latisse (bimatoprost ophthalmic solution) 0.03% prescribing information","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34f83d9d-2c64-463e-8a90-9a460fedfead"},{"title":"Lumigan (bimatoprost) 0.01% prescribing information, the glaucoma product","href":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5e67c75-db88-4372-bb07-c8dd15c97631"},{"title":"Drugs@FDA: Latisse application overview","href":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022369"},{"title":"FDA: human drug compounding","href":"https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding"},{"title":"Randomized trial of bimatoprost 0.03% for eyelash hypotrichosis (2012)","href":"https://pubmed.ncbi.nlm.nih.gov/21899919/"}],"guides":[{"title":"Bimatoprost and other lash products: cosmetic serums, extensions and latanoprost","url":"https://bimatoprostrx.com/research-guides/bimatoprost-and-other-lash-products","description":"Reports what sources say about cosmetic lash serums, eyelash extensions and latanoprost, with study designs, without ranking any product.","date":"2026-11-10"},{"title":"What the bimatoprost eyelash trials measured, and what they leave out","url":"https://bimatoprostrx.com/research-guides/bimatoprost-eyelash-trials-what-they-measured","description":"What eyelash trial abstracts measured, with concentration, size and comparison, which abstracts show a company tie, and the limits they state.","date":"2026-11-10"},{"title":"Bimatoprost, pregnancy and breastfeeding: what the Latisse label and studies say","url":"https://bimatoprostrx.com/research-guides/bimatoprost-pregnancy-and-breastfeeding","description":"Reports what the Latisse prescribing information and glaucoma medication papers say about pregnancy and breast-feeding.","date":"2026-11-10"},{"title":"Eye pressure and glaucoma: what the Latisse label and other sources say","url":"https://bimatoprostrx.com/research-guides/eye-pressure-and-glaucoma-what-sources-say","description":"What the Latisse label and other sources say about eye pressure, kept separate from the Lumigan 0.01% glaucoma label.","date":"2026-11-10"},{"title":"Eye symptoms and eyelash loss: when the sources say to see a clinician","url":"https://bimatoprostrx.com/research-guides/eye-symptoms-and-eyelash-loss-when-to-see-a-clinician","description":"Reports what the Latisse label, MedlinePlus and the NEI say about eye warning signs and other causes of eyelash loss.","date":"2026-11-10"},{"title":"How long bimatoprost takes to work and what the sources say about stopping","url":"https://bimatoprostrx.com/research-guides/how-long-bimatoprost-takes-and-what-happens-if-you-stop","description":"The time frames the Latisse label and eyelash trial abstracts give for onset and for stopping, and who each one applies to.","date":"2026-11-10"},{"title":"Iris and eyelid pigmentation: what the label and studies report","url":"https://bimatoprostrx.com/research-guides/iris-and-eyelid-pigmentation-what-sources-report","description":"What the Latisse label, chart reviews and other studies report about iris and eyelid pigmentation, kept separate by group studied.","date":"2026-11-10"},{"title":"What the Latisse prescribing information says: purpose, application and stopping","url":"https://bimatoprostrx.com/research-guides/latisse-label-what-it-says","description":"What the Latisse prescribing information says it is for, how it is applied and what it says about stopping, plus generic label and FDA page entries.","date":"2026-11-10"},{"title":"Side effects and irritation: what the label and trials report","url":"https://bimatoprostrx.com/research-guides/side-effects-and-irritation-what-sources-report","description":"The reactions and warnings in the Latisse label, one vehicle-controlled study, and the label caveat on postmarketing reports.","date":"2026-11-10"},{"title":"Changes to the skin and fat around the eye: what the label and studies report","url":"https://bimatoprostrx.com/research-guides/skin-and-fat-changes-around-the-eye","description":"What the Latisse label, observational reports and a review say about skin and fat changes around the eye, with each source design.","date":"2026-11-10"},{"title":"What bimatoprost is and how it works for eyelashes","url":"https://bimatoprostrx.com/research-guides/what-bimatoprost-is-and-how-it-works","description":"What labels and reviews say bimatoprost is, how it may act on eyelash growth, and how the eyelash product differs from the glaucoma product.","date":"2026-11-10"},{"title":"What compounded bimatoprost means: compounded drugs versus FDA-approved Latisse","url":"https://bimatoprostrx.com/research-guides/what-compounded-bimatoprost-means","description":"Reports what FDA pages say about compounded drugs, section 503A, quality and eye products, and notes that none covers compounded bimatoprost.","date":"2026-11-10"}]}